Accordingly, the researchers next plan to investigate the extent to which individual KRAS mutations influence response to EGFR inhibitors, such as cetuximab. “Future personalized patient ...

(A) Oncogene mutations were grouped together when they occurred within a given gene (e.g., 'KRAS' for all mutations ... the mutation was grouped separately (e.g., 'EGFR_T790M' for the T790M ...

Furthermore, GFH925 monotherapy was comparable to the combination regimens of other G12C inhibitors with anti-EGFR antibodies ... which includes KRAS, HRAS, and NRAS, is frequently mutated ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for adults with KRAS G12C-mutated metastatic colorectal cancer (CRC ...

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...

Preclinical data for LY4066434, a pan-KRAS inhibitor that is highly selective over HRAS and NRAS, will also be presented. Both programs are currently enrolling Phase 1 studies. All trademarks or ...